mCRPC in focus
Transcript: CYCLONE 2
Dr Neeraj Agarwal, Professor Karim Fizazi, Dr Bárbara Vieira Lima Aguiar Melão, and Professor Axel Merseburger
All transcripts are created from interview footage and directly reflect the content of the interview at the time. The content is that of the speaker and is not adjusted by Medthority.
I'll talk about CYCLONE-2 study, and this was a trial, which did not meet the primary endpoint. So we will like to keep it short. As we know that it was a phase 3 trial with abiraterone plus minus abemaciclib in first-line mCRPC setting. And just for our recollection, we know AR signalling activates CDK-46 to sustain proliferation of prostate cancer and up-regulation of cyclin D1 is a potential mechanism of resistance to AR signalling therapy. So there was a lot of preclinical rationale.
So this phase 3 trial, it was actually adaptive phase 2/phase 3 trial, which was designed to look for the efficacy of abemaciclib when added to abiraterone. Unfortunately, trial did not meet the primary endpoint of progression-free survival being improved by abemaciclib. So trial did not meet the primary endpoint, although we saw signal in patients or higher efficacy, signal of higher efficacy in patients with more aggressive disease, such as high Gleason score, patients who had de novo disease at the presentation, high PSA levels. So at this time it would be sufficient to say that we don't foresee abemaciclib being an option in our patients with metastatic prostate cancer at this current time. And we don't know if CDK-46 inhibition maybe utilised as a strategy in a more biomarker selected patients down the line.
Updates in your area
of interest
of interest
Articles your peers
are looking at
are looking at
Bookmarks
saved
saved
Days to your
next event
next event
Developed by EPG Health. This content has been developed independently of the sponsor, Pfizer, which has had no editorial input into the content. EPG Health received funding from the sponsor to help provide healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content. This content is intended for healthcare professionals only.